US4833131A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Soluble phosphorylated glucan: methods and compositions for wound healing
Assignee: Bioglucans LP
•
Filing: 1987-02-10
•
Granted: 1989-05-23
•
Expires: 2007-02-10
Abstract
Abstract A new class of soluble phosphorylated glucans is described as well as the process for making the same. According to one embodiment, the soluble phosphorylated glucan is derived from the Yeast Saccharomyces cerevisiae. The soluble phosphorylated glucans are useful for promoting the wound healing process. The soluble phosphorylated glucans are also useful for prophylactic and therapeutic applications against neoplastic, bacteria, viral, fungal and parasitic diseases. The soluble phosphorylated glucans are used either alone or in combination with a known antimicrobial agent for prophylactic and therapeutic antimicrobial applications. Additionally, they may be administered either alone or as a non-toxic adjuvant, in combination with chemotherapy. The soluble phosphorylated glucans are also useful for stimulating macrophage cells, either in vivo or in vitro, to produce a cytotoxic/cyctostatic factor effective against cancer cells.
Inventors
- 👤 David L. Williams
- 👤 I. William Browder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 10:16
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; C; C08; C08B; C08B37/00; C08B37/0006; C08B37/0024; A61P; A61P31/00; A61P31/04; A61P35/00; A61P37/00; C07; C07H; C07H3/00; C07H3/06; C12; C12P; C12P19/00; C12P19/04
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
95 words
A method for promoting healing of a dermal wound in animals and humans, comprising administering to an animal or a human affected by a dermal wound, an amount of soluble glucan which is therapeutically effective for promoting healing of a dermal wound, said soluble glucan which comprises a phosphorylated poly-[beta-(1-3) glucopyranose] chain which is characterized by: (i) the capability of dissolving in water or an aqueous solution; (ii) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (iii) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human.
Claim 2
Independent Claim
95 words
A method for promoting healing of a dermal wound in animals and humans, comprising administering to an animal or a human affected by a dermal wound, an amount of soluble glucan which is therapeutically effective for promoting healing of a dermal wound, said soluble glucan which comprises a phosphorylated poly-[beta-(1-3) glucopyranose] chain which is characterized by: (i) the capability of dissolving in water or an aqueous solution; (ii) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (iii) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human.
Claim 3
Independent Claim
111 words
A method for promoting healing of a dermal wound in animals and humans, comprising administering to an animal or a human affected by a dermal wound, an effective amount of a pharmaceutical composition which comprises (a) an amount of a soluble glucan which is therapeutically effective for promoting healing of a dermal wound, the soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (i) the capability of dissolving in water or an aqueous solution; (ii) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (iii) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human; and (b) a physiologically acceptable carrier.
Claim 4
Independent Claim
111 words
A method for promoting healing of a dermal wound in animals and humans, comprising administering to an animal or a human affected by a dermal wound, an effective amount of a pharmaceutical composition which comprises (a) an amount of a soluble glucan which is therapeutically effective for promoting healing of a dermal wound, the soluble glucan which comprises a phosphorylated poly-[beta-(1-3)glucopyranose] chain which is characterized by: (i) the capability of dissolving in water or an aqueous solution; (ii) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (iii) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human; and (b) a physiologically acceptable carrier.
Claim 5
Dependent Claim
20 words
The method according to claim 1, in which the soluble phosphorylated glucan is administered topically, intravenously, intraperitoneally, subcutaneously or orally.
Claim 6
Dependent Claim
20 words
The method according to claim 2, in which the soluble phosphorylated glucan is administered topically, intravenously, intraperitoneally, subcutaneously, or orally.
Claim 7
Dependent Claim
34 words
The method according to claim 1, in which the wound is a surgical wound, a pressure wound, a trauma wound, a burn wound, a diabetic ulcer, a venous stasis ulcer or a malignant ulceration.
Claim 8
Dependent Claim
15 words
The method according to claim 5, in which the pressure wound is a decubitus ulcer.
Claim 9
Dependent Claim
34 words
The method according to claim 2, in which the wound is a surgical wound, a pressure wound, a trauma wound, a burn wound, a diabetic ulcer, a venous stasis ulcer or a malignant ulceration.
Claim 10
Dependent Claim
15 words
The method according to claim 7, in which the pressure wound is a decubitus ulcer.
Claim 11
Independent Claim
88 words
A method for promoting healing of a dermal wound in animals and humans, comprising administering to an animal or a human affected by a dermal wound, therapeutically effective amounts of (a) an antimicrobial agent; and (b) a soluble glucan which comprises a phosphorylated poly[beta-(1-3)glucopyranose] chain which is characterized by: (i) the capability of dissolving in water or an aqueous solution; (ii) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (iii) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human.
Claim 12
Independent Claim
88 words
A method for promoting healing of a dermal wound in animals and humans, comprising administering to an animal or a human affected by a dermal wound, therapeutically effective amounts of (a) an antimicrobial agent; and (b) a soluble glucan which comprises a phosphorylated poly[beta-(1-3)glucopyranose] chain which is characterized by: (i) the capability of dissolving in water or an aqueous solution; (ii) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (iii) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human.
Claim 13
Independent Claim
88 words
A method for promoting healing of a dermal wound in animals and humans, comprising administering to an animal or a human affected by a dermal wound, therapeutically effective amounts of (a) an anti-cancer agent; and (b) a soluble glucan which comprises a phosphorylated poly[beta-(1-3)glucopyranose] chain which is characterized by: (i) the capability of dissolving in water or an aqueous solution; (ii) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (iii) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human.
Claim 14
Independent Claim
88 words
A method for promoting healing of a dermal wound in animals and humans, comprising administering to an animal or a human affected by a dermal wound, therapeutically effective amounts of (a) an anti-cancer agent; and (b) a soluble glucan which comprises a phosphorylated poly[beta-(1-3)glucopyranose] chain which is characterized by: (i) the capability of dissolving in water or an aqueous solution; (ii) being non-toxic, non-immunogenic and substantially non-pyrogenic; and (iii) the capability of exerting a profound immunobiological response when administered in vivo to an animal or to a human.
References Cited (Backward Citations)
US3081226A
Cited
US3396082A
Cited
US4493894A
Cited
US4138479A
Cited
US4202966A
Cited
US4225673A
Cited
US4237266A
Cited
US4396611A
Cited
US4340673A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-22 | 1992-11-21 | 1993-05-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-22 | 1996-11-21 | 1997-05-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-22 | 2000-11-21 | 2001-05-23 | $7700.00 | Window Closed / Lapsed |